期刊
CIRCULATION RESEARCH
卷 120, 期 12, 页码 1958-1968出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.117.311080
关键词
drug discovery; embryonic stem cells; heart failure; induced pluripotent stem cells; regeneration
资金
- Core Center for iPS Cell Research of the Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED)
- Center for the development of myocardial regenerative treatments using iPS cells of the Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED)
- Health Labour Sciences Research Grant of The Ministry of Health Labour and Welfare
- iPS Cell Research Fund
Induced pluripotent stem cells (iPSCs) are reprogrammed cells that have features similar to embryonic stem cells, such as the capacity of self-renewal and differentiation into many types of cells, including cardiac myocytes. Although initially the reprogramming efficiency was low, several improvements in reprogramming methods have achieved robust and efficient generation of iPSCs without genomic insertion of transgenes. iPSCs display clonal variations in epigenetic and genomic profiles and cellular behavior in differentiation. iPSC-derived cardiac myocytes (iPSC cardiac myocytes) recapitulate phenotypic differences caused by genetic variations, making them attractive human disease models, and are useful for drug discovery and toxicology testing. In addition, iPSC cardiac myocytes can help with patient stratification in regard to drug responsiveness. Furthermore, they can be used as source cells for cardiac regeneration in animal models. Here, we review recent progress in iPSC technology and its applications to cardiac diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据